These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 10937952)

  • 21. Is losartan superior to captopril in reducing all-cause mortality in elderly patients with symptomatic heart failure?
    Trojian TH; Jackson EA
    J Fam Pract; 2000 Aug; 49(8):759-60. PubMed ID: 10947144
    [No Abstract]   [Full Text] [Related]  

  • 22. Effects of angiotensin II receptor antagonists on [(123)I]metaiodobenzylguanidine myocardial imaging findings and neurohumoral factors in chronic heart failure.
    Shinohara H; Fukuda N; Soeki T; Sakabe K; Onose Y; Tamura Y
    Heart Vessels; 2002 Dec; 17(2):47-52. PubMed ID: 12541093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Are angiotensin II receptor blockers more efficacious than placebo in heart failure? Implications of ELITE-2. Evaluation of Losartan In The Elderly.
    Berry C; Norrie J; McMurray JJ
    Am J Cardiol; 2001 Mar; 87(5):606-7, A9. PubMed ID: 11230847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of the angiotensin-converting enzyme inhibitor alacepril on exercise capacity and neurohormonal factors in patients with mild-to-moderate heart failure.
    Kinugawa T; Osaki S; Kato M; Ogino K; Shimoyama M; Tomikura Y; Igawa O; Hisatome I; Shigemasa C
    Clin Exp Pharmacol Physiol; 2002 Dec; 29(12):1060-5. PubMed ID: 12390293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure.
    Cruden NL; Witherow FN; Webb DJ; Fox KA; Newby DE
    Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1043-8. PubMed ID: 15105283
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vasodilatation with captopril and prazosin in chronic heart failure: double blind study at rest and on exercise.
    Bayliss J; Canepa-Anson R; Norell MS; Poole-Wilson P; Sutton G
    Br Heart J; 1986 Mar; 55(3):265-73. PubMed ID: 3513808
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of losartan and captopril in ELITE II.
    Lye M
    Lancet; 2000 Sep; 356(9232):852; author reply 852-3. PubMed ID: 11022949
    [No Abstract]   [Full Text] [Related]  

  • 28. Angiotensin inhibition in severe heart failure: acute central and limb hemodynamic effects of captopril with observations on sustained oral therapy.
    Faxon DP; Halperin JL; Creager MA; Gavras H; Schick EC; Ryan TJ
    Am Heart J; 1981 May; 101(5):548-56. PubMed ID: 7013458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of losartan and captopril in ELITE II.
    Meyer FP
    Lancet; 2000 Sep; 356(9232):851; author reply 852-3. PubMed ID: 11022947
    [No Abstract]   [Full Text] [Related]  

  • 30. Evaluation of Losartan in the Elderly (ELITE) Trial: clinical implications.
    Pitt B
    Eur Heart J; 1997 Aug; 18(8):1197-9. PubMed ID: 9458406
    [No Abstract]   [Full Text] [Related]  

  • 31. Erythropoietin levels in heart failure after an acute myocardial infarction: determinants, prognostic value, and the effects of captopril versus losartan.
    Belonje AM; Westenbrink BD; Voors AA; von Haehling S; Ponikowski P; Anker SD; van Veldhuisen DJ; Dickstein K
    Am Heart J; 2009 Jan; 157(1):91-6. PubMed ID: 19081402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Urocortin 2 combined with angiotensin-converting enzyme inhibition in experimental heart failure.
    Rademaker MT; Charles CJ; Nicholls MG; Richards AM
    Clin Sci (Lond); 2008 May; 114(10):635-42. PubMed ID: 18052934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circadian variation in blood pressure and heart rate in nonhypertensive congestive heart failure.
    Giles TD; Roffidal L; Quiroz A; Sander G; Tresznewsky O
    J Cardiovasc Pharmacol; 1996 Dec; 28(6):733-40. PubMed ID: 8961069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determinants of acute and long-term response to converting enzyme inhibitors in congestive heart failure.
    Levine TB; Cohn JN
    Am Heart J; 1982 Nov; 104(5 Pt 2):1159-64. PubMed ID: 6182784
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study.
    Vantrimpont P; Rouleau JL; Ciampi A; Harel F; de Champlain J; Bichet D; Moyé LA; Pfeffer M
    Eur Heart J; 1998 Oct; 19(10):1552-63. PubMed ID: 9820995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The circulating renin-angiotensin system during treatment with metoprolol or captopril in patients with heart failure due to non-ischaemic dilated cardiomyopathy.
    Jansson K; Dahlström U; Karlberg BE; Karlsson E; Nylander E; Nyquist O; Karlberg KE
    J Intern Med; 1999 May; 245(5):435-43. PubMed ID: 10363743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does the addition of losartan improve the beneficial effects of ACE inhibitors in patients with anterior myocardial infarction? A pilot study.
    Di Pasquale P; Bucca V; Scalzo S; Cannizzaro S; Giubilato A; Paterna S
    Heart; 1999 Jun; 81(6):606-11. PubMed ID: 10336919
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril.
    Rouleau JL; Packer M; Moyé L; de Champlain J; Bichet D; Klein M; Rouleau JR; Sussex B; Arnold JM; Sestier F
    J Am Coll Cardiol; 1994 Sep; 24(3):583-91. PubMed ID: 7915733
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and neurohumoral differences between spirapril and captopril in mild to moderate chronic congestive heart failure.
    van den Broek SA; de Graeff PA; van Veldhuisen DJ; van Gilst WH; Hillege H; Wesseling H; Lie KI
    J Card Fail; 1997 Sep; 3(3):165-71. PubMed ID: 9330124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EXP3174, the AII antagonist human metabolite of losartan, but not losartan nor the angiotensin-converting enzyme inhibitor captopril, prevents the development of lethal ischemic ventricular arrhythmias in a canine model of recent myocardial infarction.
    Lynch JJ; Stump GL; Wallace AA; Painter CA; Thomas JM; Kusma SE; Gould RJ; Grossman W
    J Am Coll Cardiol; 1999 Sep; 34(3):876-84. PubMed ID: 10483973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.